How many days should ticagrelor (Brilinta) be stopped prior to a skin graft?

Ticagrelor (Brilinta) Should Be Held for 3-5 Days Before Skin Graft Surgery

For elective skin graft procedures, stop ticagrelor (Brilinta) 3-5 days before surgery to minimize bleeding risk while balancing the need for adequate hemostasis.

Evidence-Based Recommendation

The most recent and authoritative guidance comes from the 2022 American College of Chest Physicians (ACCP) perioperative management guideline, which specifically recommends stopping ticagrelor 3 to 5 days before elective non-cardiac surgery 1. This represents a conditional recommendation based on very low certainty evidence, but it reflects the best available consensus for balancing bleeding risk against thrombotic complications.

Practical Implementation

Standard Approach for Skin Grafts:

• Last dose of ticagrelor: 3-5 days before surgery (ideally 5 days for maximum safety)
• Resume ticagrelor: Within 24 hours after surgery once adequate hemostasis is achieved 1
• Continue aspirin perioperatively if the patient is on dual antiplatelet therapy, unless bleeding risk is exceptionally high

Why 3-5 Days?

The pharmacology of ticagrelor supports this timeframe. Unlike clopidogrel, ticagrelor is a reversible P2Y12 inhibitor with a shorter half-life, theoretically allowing faster recovery of platelet function 2. However, clinical data demonstrates that:

• Within 0-2 days: Significantly elevated bleeding risk persists 3, 4
• At 3 days: Bleeding risk remains elevated but begins to normalize 3, 5
• At 5 days: Platelet function recovery is sufficient in most patients 6, 4

Research shows that approximately 25% of patients still have inadequate platelet function recovery at 72 hours 7, making the 5-day window safer for procedures where bleeding control is critical, such as skin grafts.

Context-Specific Considerations

For Urgent/Semi-Urgent Cases:

If the skin graft cannot be delayed 5 days (e.g., burn injury, infected wound requiring coverage), the minimum safe interval is 3 days 1, 7. Surgery performed within 48 hours of the last ticagrelor dose carries substantially higher bleeding risk 3, 5.

Comparison to Other Antiplatelet Agents:

• Clopidogrel: Hold 5 days 1, 8
• Prasugrel: Hold 7 days 1, 8
• Aspirin alone: Hold 3-7 days (or continue if bleeding risk is acceptable) 1

Ticagrelor's 3-5 day window is shorter than prasugrel but similar to clopidogrel, despite its reversible binding mechanism not translating to clinically faster recovery in surgical bleeding outcomes 2.

Critical Pitfalls to Avoid

1. Do not assume ticagrelor's reversible binding means you can operate sooner: Clinical bleeding data does not support operating before 3 days 2, 4

2. Do not routinely use platelet function testing to guide timing: The 2022 ACCP guideline suggests against routine platelet function testing for surgical timing decisions 1, 9

3. Do not delay resumption unnecessarily: Restart ticagrelor within 24 hours post-operatively once hemostasis is secure to minimize thrombotic risk 1

4. Consider the indication: If ticagrelor was prescribed for recent acute coronary syndrome (ACS) or coronary stent (especially within 6-12 weeks), consult cardiology before stopping, as thrombotic risk may outweigh bleeding risk 1, 8

Special Populations

Patients with Recent Coronary Stents:

For patients with drug-eluting stents placed within 6-12 weeks, the decision to hold ticagrelor requires careful risk-benefit assessment and often cardiology consultation 1. In these high-thrombotic-risk patients, continuing one antiplatelet agent (typically aspirin) while holding ticagrelor may be reasonable.

Renal Impairment:

No specific adjustment to the 3-5 day holding period is required for renal dysfunction, as ticagrelor is primarily hepatically metabolized 10.

Algorithm for Decision-Making

Step 1: Determine urgency of skin graft

• Elective → Proceed to Step 2
• Urgent (cannot wait 3 days) → Consult surgery and cardiology; consider proceeding with increased bleeding precautions

Step 2: Assess thrombotic risk

• Recent ACS or stent (<6-12 weeks) → Cardiology consultation required
• Stable CAD or other indication → Proceed to Step 3

Step 3: Hold ticagrelor

• Optimal: 5 days before surgery
• Acceptable: 3 days before surgery (if cannot delay further)
• High-risk: <3 days (significantly increased bleeding risk)

Step 4: Resume therapy

• Restart within 24 hours post-op once hemostasis achieved
• Use maintenance dose (90 mg twice daily), not loading dose